ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer our patients more good days. ImmunoGen call this it's commitment to TARGET A BETTER NOW™. ELAHERE® is a trademark of ImmunoGen, Inc.